share_log

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility

EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility

獨家報道：Lineage Cell在美國建立新的研發設施，擴大以色列設施
Benzinga Real-time News ·  2022/10/03 07:43
  • Lineage Cell Therapeutics Inc (NYSE:LCTX) has opened a new research and development facility in Carlsbad, California.
  • What Happened: The new Carlsbad facility will broaden the company's R&D capabilities in the U.S. and support the development of current and future allogeneic cell transplant programs.
  • The company has also announced the expansion of its manufacturing facility in Jerusalem, Israel, which will increase its infrastructure, including developing and optimizing larger-scale clinical manufacturing processes and continued execution under its ongoing collaboration with Roche Holdings AG (OTC:RHHBY) and Genentech for RG6501 (OpRegen).
  • RG6501 is a retinal pigment epithelium cell replacement therapy that has completed enrollment in a Phase 1/2a trial for geographic atrophy secondary to age-related macular degeneration.
  • Why It Matters: "The additional capacity also can help us become an even more capable partner in prospective alliances for new products and allow us to explore additional uses for our current cell transplant programs," commented Brian Culley, Lineage CEO.
  • "The modest investments we are making today, partially offset by the termination of the lease for our research facility in Alameda, California, in January of next year, will help centralize our operations and put us in a position of greater readiness for future success," Culley added.
  • Price Action: LCTX shares closed lower by 1.74% at $1.13 on Friday.
  • 世系細胞治療公司(紐約證券交易所股票代碼：LCTX)在加利福尼亞州卡爾斯巴德開設了一家新的研發機構。
  • 發生的事情：新的卡爾斯巴德工廠將擴大該公司在美國的研發能力，並支持當前和未來異基因細胞移植計劃的發展。
  • 該公司還宣佈擴大其在以色列耶路撒冷的製造設施，這將增加其基礎設施，包括開發和優化更大規模的臨牀製造流程，並在其持續合作下繼續執行羅氏控股公司(場外交易：RHHBY)和基因泰克用於RG6501(OpRegen)。
  • RG6501是一種視網膜色素上皮細胞替代療法，已經完成了1/2a期試驗，用於治療繼發於老年性黃斑變性的地理萎縮。
  • 為什麼這很重要：Lineage首席執行官布萊恩·卡利評論説：“額外的產能還可以幫助我們在未來的新產品聯盟中成為一個更有能力的合作伙伴，並使我們能夠探索我們目前細胞移植計劃的其他用途。”
  • 卡爾利補充説：“我們今天進行的少量投資，部分抵消了明年1月終止我們在加利福尼亞州阿拉米達的研究設施的租約，這將有助於集中我們的業務，使我們為未來的成功做好更好的準備。”
  • 價格行動：LCTX股價週五收低1.74%，報1.13美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論